Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome

被引:14
作者
El-Assaad F. [1 ,2 ]
Krilis S.A. [1 ,2 ]
Giannakopoulos B. [1 ,2 ]
机构
[1] St. George Hospital, Department of Infectious Diseases, Immunology, and Sexual Health, Level 1, 2 South Street, Kogarah, 2217, NSW
[2] St. George and Sutherland Clinical School, Faculty of Medicine, University of New South Wales Australia, Research and Education Centre, Level 3, 4 - 10 South St, Kogarah, 2217, NSW
关键词
Antiphospholipid syndrome; Beta-2; Glycoprotein-1; Oxidative modification;
D O I
10.1186/s12959-016-0115-z
中图分类号
学科分类号
摘要
The antiphospholipid syndrome (APS) is an autoimmune disease characterised by a procoagulant state that predisposes to recurrent thrombosis and miscarriages. Two major discoveries have advanced our understanding of the underlying complex pathogenesis of the APS. The first was the discovery that beta-2 glycoprotein-1 (β2GPI) is the major auto antigen in APS. The second was the discovery in more recent years that β2GPI contains allosteric disulphide bonds susceptible to posttranslational modification that may be involved in the development of autoantibodies in APS. The main allosteric disulphide bond in the fifth domain of β2GPI can exist in two redox states: free thiol or oxidised. It is the conformational transformation of β2GPI from its free thiol form to its more immunogenic oxidised form that exposes neo-epitopes on the first and fifth domains. The purpose of this review is to highlight the recent findings on the posttranslational forms of β2GPI in the pathogenesis of APS. We suggest that novel assays quantitating the different redox forms of β2GPI in plasma or serum may be used to supplement existing clinical and laboratory assays to more accurately stratify risk of thrombosis or miscarriage in APS patients. © 2016 The Author(s).
引用
收藏
相关论文
共 47 条
[1]  
Passam F., Krilis S., Laboratory tests for the antiphospholipid syndrome: current concepts, Pathology, 36, 2, pp. 129-138, (2004)
[2]  
Krilis S.A., Giannakopoulos B., Laboratory methods to detect antiphospholipid antibodies, Hematol Am Soc Hematol Educ Program, 2014, 1, pp. 321-328, (2014)
[3]  
Giannakopoulos B., Krilis S.A., The pathogenesis of the antiphospholipid syndrome, N Engl J Med, 368, 11, pp. 1033-1044, (2013)
[4]  
Erkan D., Lockshin M.D., APS ACTION-antiphospholipid syndrome alliance for clinical trials and international networking, Lupus, 21, 7, pp. 695-698, (2012)
[5]  
Giannakopoulos B., Et al., How we diagnose the antiphospholipid syndrome, Blood, 113, 5, pp. 985-994, (2009)
[6]  
Miyakis S., Et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 2, pp. 295-306, (2006)
[7]  
Pengo V., Et al., Diagnosis and therapy of antiphospholipid syndrome, Pol Arch Med Wewn, 125, 9, pp. 672-677, (2015)
[8]  
Giannakopoulos B., Krilis S.A., How I treat the antiphospholipid syndrome, Blood, 114, 10, pp. 2020-2030, (2009)
[9]  
McNeil H.P., Et al., Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H), Proc Natl Acad Sci U S A, 87, 11, pp. 4120-4124, (1990)
[10]  
Miyakis S., Giannakopoulos B., Krilis S.A., Beta 2 glycoprotein I--function in health and disease, Thromb Res, 114, 5-6, pp. 335-346, (2004)